• Juan C López-Hernández, Edwin S Vargas-Cañas, S Alexander Estrada, and Javier Galnares-Olalde.
• Neuromuscular Diseases Clinic.
• Gac Med Mex. 2023 Jan 1; 159 (4): 315321315-321.

BackgroundDuring the COVID-19 pandemic, an increase in the number of Guillain-Barre syndrome (GBS) cases has been reported.ObjectiveTo describe the clinical characteristics and prognosis of patients with GBS before and during the COVID-19 pandemic.Material And MethodsProspective cohort of GBS patients divided in two subgroups: before (2018-2019) and during (2020-2021) the COVID-19 pandemic. Clinical and paraclinical characteristics, as well as deaths, were recorded. A good prognosis was defined as independent ambulation recovery at three months.ResultsTwo-hundred and one patients were included (123 during and 78 before the pandemic), out of whom 69% were males; age was 45 ± 16 years, and there was 2.5% of in-hospital deaths. During the pandemic, a higher frequency of the demyelinating variant (50%), bulbar cranial nerves involvement (44% vs. 28%), prior history of vaccination (16% vs. 0%), and a lower MRC score (30 ± 16.7 vs. 34.3 ± 17.7) were documented. An increase in the number of cases was observed from July to September (38 vs. 13). There were no significant differences in independent ambulation recovery or in the number of deaths.ConclusionsDuring the COVID-19 pandemic, a higher number of GBS cases were treated, out of which 16% were associated with the SARS-CoV-2 vaccine; patients treated during the pandemic did not have a worse prognosis.Copyright: © 2023 Permanyer.

19 keywords...

hide…